Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
Verified emails & LinkedIn for founders across this portfolio.
Plexium develops a targeted protein degradation platform to find new therapies for cancer and other diseases.
Incyclix Bio develops small molecule inhibitors of CDKs for the treatment of advanced and resistant cancers.
Arvinas advances therapies degrading disease-causing proteins for life-threatening diseases, from discovery to commercialization.
Superluminal Medicines is a generative biological and chemical company that innovates drug discovery and development processes.
CANbridge Pharmaceuticals is a bio-pharmaceutical company accelerating development and commercialization of specialty healthcare .
Iterum Therapeutics is a clinical-stage pharmaceutical company that develops significantly differentiated anti-infectives.
Pahr Therapeutics is a clinical stage business, is to create innovative ways to treat pulmonary arterial hypertension.
Spyglass Pharma provides medicine for ophthalmic diseases.
Taysha Gene Therapies develops treatments to eradicate severe and life-threatening monogenic diseases of the central nervous system.
Stylus Medicine is on a quest to create disease-treating agents for the next generation based on the groundbreaking work of its founders.
Vaxess Technologies engages in developing biomedical innovations with a focus on improving access to vaccines.
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.
Surrozen is a biopharmaceutical that focuses on unlocking the body’s regenerative power to treat injury and disease.
Curevo is a clinical-stage biotechnology company developing next-generation, non-mRNA vaccines for infectious diseases.
Claris Biotherapeutics develops a topical formulation intended to cure corneal wounds, ulcers, and scars.
Genetix Biotherapeutics develops and delivers approved gene therapies for severe rare genetic diseases like sickle cell.
Abcuro develops immunotherapies to treat autoimmunity and cancer.
GH Research is a biopharmaceutical company developing novel therapies for the management of mental illness.
89bio is a biopharmaceutical company that develops clinical-stage therapies for liver and cardiometabolic diseases.
Third Harmonic Bio is a clinical-stage company developing a first-in-class, highly selective, and oral kit inhibitor.
Rivus Pharmaceuticals operates as a biopharmaceutical company dedicated to improving cardio-metabolic health.
Be Biopharma develops engineered B cell medicines for serious genetic diseases.
Inhibrx is a clinical-stage biotechnology company that focuses on developing a broad pipeline of biologic therapeutic candidates.
Verdiva Bio creates cutting-edge treatments that improve results for patients with obesity and cardiometabolic diseases.
RA Capital Management has invested in 453 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
RA Capital Management's top investment sectors include Biotechnology, Health Care, Pharmaceutical, Medical, Therapeutics. The firm invests across 14 different industry categories.
Among tracked funding rounds, Verdiva Bio received $411.0M in a Series A round. RA Capital Management's total known invested capital is $49.1B.
RA Capital Management's average investment size is $128.6M across its portfolio of 453 companies.
Recent RA Capital Management portfolio additions include Plexium, Incyclix Bio, Arvinas, Superluminal Medicines, CANbridge Pharmaceuticals. These companies were founded in 2020 or later.